CAS: 1776112-90-3

Mavelertinib (PF-06747775) is an EGFR tyrosine kinase (EGFR TKI) inhibitor that inhibits T790M/L858R and can be used to study tumours.

PF 06747775 is a growth factor that binds to the epidermal growth factor receptor (EGFR) and toll-like receptor 4 (TLR4), thereby inhibiting their downstream signaling. PF 06747775 has been shown to be effective in treating cancer, inflammatory diseases, and other diseases characterized by uncontrolled cell proliferation. It also inhibits the activity of CDK4/6, which regulates the G0/G1 phase transition in cells. PF 06747775 is administered systemically as a microsphere formulation for oral delivery. The drug is currently in Phase II clinical trials for its potential use as a treatment for cancer and inflammatory diseases.